TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25881690

Group type: EXPERIMENTAL
Intervention: Mitiglinide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination treatment (Mitiglinide + Sitagliptin)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 24
Study: 23883803

Group type: EXPERIMENTAL
Intervention: Nasal steroid (Ns) + antihistamine (Ah)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nasal steroid (Ns)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 80
Study: 22042283

Group type: EXPERIMENTAL
Intervention: Oral voriconazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low dose intravenous amphotericin B (AmB)
Number of subjects: 100
Study: 19536744

Group type: EXPERIMENTAL
Intervention: Split-mouth design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16316744

Group type: COMPARATOR
Intervention: Zonisamide 500 mg/day
Number of subjects: 848

Group type: COMPARATOR
Intervention: Zonisamide 400-600 mg/day
Number of subjects: 848

Group type: COMPARATOR
Intervention: Zonisamide (various doses 100-500 mg/day)
Number of subjects: 848

Group type: COMPARATOR
Intervention: Zonisamide
Number of subjects: 848
Study: 15013305

Group type: EXPERIMENTAL
Intervention: IV thymoglobulin (ATG 5 mg/kg/d) plus methylprednisolone (500 mg/d) plus azathiopurine (2 mg/kg/d) on days 0 and 1 after renal transplantation.
Number of subjects: 39
Study: 11312402

Group type: EXPERIMENTAL
Intervention: Atopic asthmatics treated with beta(2) agonists alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atopic asthmatics treated with corticosteroids
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-asthmatic control subjects
Number of subjects: 25
Study: 9562357

Group type: EXPERIMENTAL
Intervention: Cold exposure (-15 degrees C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.4 mg x 3) administered 10 min before exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ambient temperature (23 degrees C)
Number of subjects: 8
Study: 7944706

Group type: EXPERIMENTAL
Intervention: Antithrombin III (1,000 units)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no antithrombin III supplementation)
Number of subjects: 21
Study: 3067339

Group type: EXPERIMENTAL
Intervention: Olsalazine capsules, 1 g b.d. for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 30
Study: 29035633

Group type: EXPERIMENTAL
Intervention: Technology assisted therapy for separation anxiety (TTSA)
Number of subjects: 6
Study: 28073668

Group type: EXPERIMENTAL
Intervention: Cilostazol treatment
Number of subjects: 399

Group type: COMPARATOR
Intervention: Cilostazol-free treatment
Number of subjects: 399
Study: 25387655

Group type: EXPERIMENTAL
Intervention: Strong Acid Electrolyzed Water (SAEW)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 44
Study: 23506518

Group type: EXPERIMENTAL
Intervention: Surgery and postoperative physical therapy
Number of subjects: 351

Group type: COMPARATOR
Intervention: Standardized physical‐therapy regimen
Number of subjects: 351
Study: 21153559

Group type: EXPERIMENTAL
Intervention: Intervention (Interpersonal Psychotherapy based intervention)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 19496829

Group type: EXPERIMENTAL
Intervention: Phenothiazines
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Other active agents
Number of subjects: 13

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 13
Study: 16861091

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg QD
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg QD
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Armodafinil (combined group)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 12644518

Group type: EXPERIMENTAL
Intervention: Low-Dye strap
Number of subjects: 0
Study: 11156125

Group type: EXPERIMENTAL
Intervention: Open heart surgery (OHS)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 171
Study: 9291281

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with standardized cat dander extract
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7686705

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS) 7.5% combined with hydroxyethylstarch (HAES)
Number of subjects: 41
Study: 3105558

Group type: EXPERIMENTAL
Intervention: Astemizole 5 mg/d
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg/d
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Astemizole 20 mg/d
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29587288

Group type: EXPERIMENTAL
Intervention: Intravenous sodium thiosulfate (IV STS) 12.5 g during the last HD hour twice weekly for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous sodium thiosulfate (IV STS)
Number of subjects: 50
Study: 27510000

Group type: EXPERIMENTAL
Intervention: Application of social marketing theory and health belief model program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal services (Control)
Number of subjects: 92
Study: 25373724

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) combined with standard treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham tDCS combined with standard treatment
Number of subjects: 31
Study: 22575567

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine IV doses starting at 1.5 mg with 1.5-mg increments
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine IV doses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine pharmacokinetics
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine pharmacodynamics
Number of subjects: 22
Study: 20413121

Group type: EXPERIMENTAL
Intervention: Nurse clinic combined with telephone follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nurse clinic only)
Number of subjects: 0
Study: 17390761

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl, 180 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desloratadine, 5 mg
Number of subjects: 0
Study: 16140701

Group type: EXPERIMENTAL
Intervention: Endoscopic removal (surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 60
Study: 12010586

Group type: COMPARATOR
Intervention: High-carbohydrate-high-glycaemic index (GI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-carbohydrate-low-glycaemic index (GI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-carbohydrate-high-monounsaturated fat (MUFA)
Number of subjects: 35
Study: 9449869

Group type: EXPERIMENTAL
Intervention: Laparoscopic exploration of common bile duct (LECBD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Postoperative endoscopic retrograde cholangiography (ERCP)
Number of subjects: 80
Study: 7667377

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2611075

Group type: EXPERIMENTAL
Intervention: i.v. diazepam 0.15 mg kg‐1
Number of subjects: 26

Group type: COMPARATOR
Intervention: i.v. midazolam 0.07 mg kg‐1
Number of subjects: 26
Study: 993925

Group type: EXPERIMENTAL
Intervention: High rate of intravenous infusion (10.3 ml/kg/hr)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low rate of intravenous infusion (3.6 ml/kg/hr)
Number of subjects: 20
Study: 31935353

Group type: EXPERIMENTAL
Intervention: Geriatric interdisciplinary home rehabilitation for a maximum of 10 weeks
Number of subjects: 205

Group type: COMPARATOR
Intervention: Inhospital geriatric care
Number of subjects: 205
Study: 30827767

Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary files (Dentsply Maillefer, Ballaigues, Switzerland)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: OneShape rotary files (Micro‐Mega, Besancon, France)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: WaveOne reciprocal system (Dentsply Maillefer, Ballaigues, Switzerland)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hand files (control 2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No intervention (control 1)
Number of subjects: 150
Study: 27349705

Group type: EXPERIMENTAL
Intervention: Pitavastatin plus ezetimibe (target LDL-C <70mg/dL)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Pitavastatin monotherapy (target LDL-C 90-100mg/dL)
Number of subjects: 1734
Study: 26944583

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) applied for 90 seconds in three sessions
Number of subjects: 20
Study: 25000163

Group type: EXPERIMENTAL
Intervention: TheraBite® Jaw Motion Rehabilitation System (TB)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard physical therapy (PT) exercises
Number of subjects: 96

Group type: COMPARATOR
Intervention: Both TB and standard PT
Number of subjects: 96
Study: 21996058

Group type: EXPERIMENTAL
Intervention: Exercise program (EX) - attended exercise facility three times/week for 52 weeks, daily jumping exercises at home, calcium supplementation.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (CON) - continued usual care, calcium supplementation.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exercise program (EX)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 39
Study: 20403926

Group type: EXPERIMENTAL
Intervention: Intensive management of screen-detected patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study: 17629159

Group type: EXPERIMENTAL
Intervention: Colposcopists' agreement with consensus diagnoses
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Use of ECC
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Factors influencing agreement
Number of subjects: 72
Study: 16216024

Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty followed by Sr/Y‐90 beta‐brachytherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard Balloon (SB) angioplasty followed by Sr/Y‐90 beta‐brachytherapy
Number of subjects: 100
Study: 11966923

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Braun Oral‐B Plaque Remover 3‐D)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual soft toothbrush (Oral‐B Squish‐grip brush)
Number of subjects: 40
Study: 10195511

Group type: COMPARATOR
Intervention: Propofol (50 microg x kg(‐1) x min(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methohexital (40 microg x kg(‐1) x min(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methohexital (29.4 +/‐ 2.7 microg x kg(‐1) x min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol (36.8 +/‐ 15.9 microg x kg(‐1) x min(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methohexital and Propofol
Number of subjects: 60
Study: 7773730

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 22
Study: 1639941

Group type: EXPERIMENTAL
Intervention: 0.25 mg cetrorelix
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5 mg cetrorelix
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.0 mg cetrorelix
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.0 mg cetrorelix
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5.0 mg cetrorelix
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0 mg cetrorelix)
Number of subjects: 30
Study: 6089307

Group type: EXPERIMENTAL
Intervention: Enalapril (40 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lisinopril (40 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both enalapril and lisinopril
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31831056

Group type: EXPERIMENTAL
Intervention: Gantenerumab 1200 mg every 4 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Gantenerumab 225 mg
Number of subjects: 67
Study: 29747252

Group type: EXPERIMENTAL
Intervention: H‐UPPP combined with tongue base radiofrequency ablation (experimental group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: H‐UPPP (control group)
Number of subjects: 62
Study: 26792672

Group type: EXPERIMENTAL
Intervention: School feeding programme group (standard government programme)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Home-grown school feeding (standard programme + innovative pilot project)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (intervention delayed by at least 3 years)
Number of subjects: 116
Study: 28726022

Group type: EXPERIMENTAL
Intervention: On-medication condition
Number of subjects: 4

Group type: COMPARATOR
Intervention: Off-medication condition
Number of subjects: 4
Study: 23472142

Group type: EXPERIMENTAL
Intervention: DHI Score ≥50
Number of subjects: 88

Group type: COMPARATOR
Intervention: DHI Score <50
Number of subjects: 88
Study: 22031049

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste used at night after demineralization episodes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste used in the morning before demineralization episodes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-fluoride placebo toothpaste
Number of subjects: 12
Study: 19483453

Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of 0.25% bupivacaine (40 ml) and 20 ml in 4 ports (5 ml each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of 0.25% bupivacaine
Number of subjects: 40
Study: 18694194

Group type: EXPERIMENTAL
Intervention: Diabetes-STAR disease management program integrated with an online patient portal
Number of subjects: 331
Study: 15277913

Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Laryngeal Tube Suction (LTS)
Number of subjects: 150
Study: 11504277

Group type: EXPERIMENTAL
Intervention: Buspirone extended-release (ER) formulation, 30 mg once daily for 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Buspirone immediate-release (IR) formulation, 15 mg twice daily for 7 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Buspirone extended-release (ER) formulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Buspirone immediate-release (IR) formulation
Number of subjects: 36
Study: 9489934

Group type: EXPERIMENTAL
Intervention: Nicotine cigarette (0.8 mg nicotine)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham cigarette
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nicotine tablet
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Instruction of receiving nicotine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Instruction of receiving sham
Number of subjects: 96
Study: 7531423

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 2336928

Group type: EXPERIMENTAL
Intervention: 0.5, 1.0, 2.0 or 4.0% D-timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25% L-timolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4.0% D-timolol
Number of subjects: 0
Study: 7212475

Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg dose of verapamil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dose of verapamil (open-label phase)
Number of subjects: 20
Study: 30889043

Group type: EXPERIMENTAL
Intervention: Acute running (70% V˙O2max) followed by a standardized meal (1170 kcal, 43% CHO, 17% PRO, 40% fat)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (rest) followed by a standardized meal (1170 kcal, 43% CHO, 17% PRO, 40% fat)
Number of subjects: 15
Study: 28768334

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help (GSH-I)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Individual face-to-face cognitive behavioral therapy (CBT)
Number of subjects: 178
Study: 23269112

Group type: EXPERIMENTAL
Intervention: Peer Coach and Office Staff Support Intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control Group (noncompliers)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Intention-to-treat analysis
Number of subjects: 280
Study: 23419791

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control Treatment (CT)
Number of subjects: 33
Study: 21856778

Group type: COMPARATOR
Intervention: Local Anaesthetic Infiltration (LAI)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Rectus Sheath Block (RSB)
Number of subjects: 52
Study: 19221905

Group type: EXPERIMENTAL
Intervention: Tone burst stimuli measuring summating potentials (SP)
Number of subjects: 2717

Group type: COMPARATOR
Intervention: Click evoked summating potential versus action potential ratio (SP/AP)
Number of subjects: 2717
Study: 17124239

Group type: EXPERIMENTAL
Intervention: Three-piece acrylic hydrophobic IOL
Number of subjects: 74

Group type: COMPARATOR
Intervention: One-piece acrylic hydrophobic IOL
Number of subjects: 74
Study: 15016251

Group type: EXPERIMENTAL
Intervention: Experimental gingivitis (test quadrant)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (contralateral quadrant)
Number of subjects: 96
Study: 11150970

Group type: EXPERIMENTAL
Intervention: D90A CuZn-SOD mutation patients
Number of subjects: 8

Group type: COMPARATOR
Intervention: Multiple sclerosis patients
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 8
Study: 9444470

Group type: EXPERIMENTAL
Intervention: Sounds produced by familiar natural instruments (violin, flute, guitar, drum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sounds played backwards (less recognizable)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both familiar and unfamiliar sounds
Number of subjects: 0
Study: 7910838

Group type: EXPERIMENTAL
Intervention: Zidovudine with interferon-alpha (IFN-alpha) (n = 25)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Zidovudine alone (n = 20)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (Zidovudine and IFN-alpha, Zidovudine alone)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Zidovudine and IFN-alpha
Number of subjects: 45

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 45
Study: 2293257

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 229547

Group type: EXPERIMENTAL
Intervention: Diet rich in polyunsaturated acids
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diet rich in oleic acids
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 10
Study: 31782930

Group type: COMPARATOR
Intervention: Vigorous-intensity continuous training (VICT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Whole-body Tabata
Number of subjects: 52

Group type: COMPARATOR
Intervention: No-exercise control (CTL)
Number of subjects: 52
Study: 31040197

Group type: EXPERIMENTAL
Intervention: Long-term (LT) methimazole treatment (n = 24)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Short-term (ST) methimazole treatment (n = 24)
Number of subjects: 66
Study: 28213368

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 17113

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 17113
Study: 25462662

Group type: EXPERIMENTAL
Intervention: Lifetime substance users (excluding cannabis)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Thirty day drug use frequency for opiates and alcohol
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Lifetime history of non-clinical substance use
Number of subjects: 242
Study: 23627650

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 60 µg alprostadil over 3 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo infusion over 3 weeks
Number of subjects: 33
Study: 21266651

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Standard home blood glucose monitoring
Number of subjects: 436
Study: 18771480

Group type: EXPERIMENTAL
Intervention: Topical levofloxacin 0.5% administered as two preoperative drops and three postoperative drops
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical levofloxacin 0.5%
Number of subjects: 30
Study: 16478626

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 231
Study: 14739817

Group type: EXPERIMENTAL
Intervention: Basal group (12 ml/h basal, 0.05-ml patient-controlled bolus dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Basal-bolus group (8 ml/h basal, 4 ml bolus)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bolus group (0.3 ml/h basal, 9.9 ml bolus)
Number of subjects: 30
Study: 12575604

Group type: EXPERIMENTAL
Intervention: Tuoli Xiaodu Powder (TLXDP) given to Group I before and 7 days after surgical operation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (Group II) did not receive TLXDP
Number of subjects: 38
Study: 9336816

Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine 5% with epinephrine 1:50,000
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Iontophoresis of mepivacaine 2% with epinephrine 1:50,000
Number of subjects: 36

Group type: COMPARATOR
Intervention: Preservative-free 0.9% NaCl (control)
Number of subjects: 36
Study: 7896428

Group type: EXPERIMENTAL
Intervention: Flat sheet silicone membrane oxygenator (Avecor Kolobow 800‐2A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hollow fibre membrane oxygenator (Dideco Masterflo D‐701)
Number of subjects: 20
Study: 3684126

Group type: EXPERIMENTAL
Intervention: Tocolytic (ritodrine hydrochloride 200 micrograms/minute for 20 minutes via continuous intravenous infusion)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No tocolytic
Number of subjects: 58

Group type: COMPARATOR
Intervention: No tocolytic (after unsuccessful attempt)
Number of subjects: 58